Apremilast Therapeutic Cheat Sheet
apremilast
by Alexis Carrington, MD on
Apremilast (OTEZLA®) is a twice daily oral medication that is FDA approved for adults with plaque psoriasis, psoriatic arthritis and oral ulcers associated with Behçet’s Disease.1 This drug is being extended as an off-label treatment to target inflammation in a number of different conditions. This Therapeutic Cheat Sheet will focus on apremilast and its applications for different dermatologica …
Valacyclovir Therapeutic Cheat Sheet
Valacyclovir
by Adrianna Gonzalez Lopez, MD on
Herpesviridae is a family of ubiquitous viral pathogens leading to a wide array of diseases in humans, and includes viruses such as herpes simplex virus 1 (HSV-1) and 2 (HSV-2), herpes/varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV) and herpes viruses 6 (HHV-6), 7 (HHV-7) and 8 (HHV-8). Mucocutaneous herpetic infections are frequently encountered in dermatology, and s …
Doxepin Therapeutic Cheat Sheet
Doxepin
by Michael J. Visconti, DO on
As dermatologists, pruritus (or itch) is one of the most frequent symptoms that we encounter. The broad spectrum of itch severity in patients with various dermatologic conditions suggests a need for a host of “tools” or medications that dermatologists should have in their toolbox. In this publication, we continue our Therapeutic Cheat Sheet series by highlighting the uses of Doxepin in dermato …
Upadacitinib Therapeutic Cheat Sheet
Upadacitinib
by Alexis Carrington, MD on
Upadacitinib (RINVOQ®) is a once daily oral medication that is FDA approved for a variety of conditions including psoriatic arthritis and atopic dermatitis. Jak inhibitors, like upadacitinib, are a class of drugs showing to be effective in treating inflammatory conditions. Upadacitnib is not only being used to treat  rheumatoid arthritis and psoriatic arthritis, but  was recently FDA approved i …
Omalizumab Therapeutic Cheat Sheet
Omalizumab
by Alexis Carrington, MD on
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr …
error

Enjoy this blog? Please spread the word :)